The response to the COVID-19 crisis implied an unprecedented involvement of the European Union (EU) executive in public health matters. In June 2020, the Member States agreed upon a joint EU Vaccines Strategy, whereby the European Commission was enabled to negotiate, support and allocate vaccine doses on their behalf. Entailing political and redistributive choices, the Commission’s centralised procurement presents some innovative patterns when compared to traditional EU executive action. This paper will focus on the institutionalisation of such patterns within the legal framework of the Health Emergency Preparedness and Response Authority (HERA). Did EU administrative law offer appropriate tools for this process? Or did the EU merely formalise the procedural and organisational schemes set up during the crisis? Answers to these questions will contribute to a fuller understanding of the administrative dimension of the new European Health Union and shed light on some recent evolutions of the EU administrative system.

中文翻译：

---

欧盟疫苗战略：欧盟公共卫生错失良机？

对 COVID-19 危机的反应意味着欧盟 (EU) 行政部门前所未有地参与公共卫生事务。2020 年 6 月，成员国商定了一项欧盟疫苗联合战略，据此，欧盟委员会能够代表它们谈判、支持和分配疫苗剂量。与传统的欧盟行政行为相比，委员会的集中采购涉及政治和再分配选择，呈现出一些创新模式。本文将重点关注此类模式在卫生应急准备和响应机构 (HERA) 的法律框架内的制度化。欧盟行政法是否为这一过程提供了适当的工具？还是欧盟只是将危机期间制定的程序和组织计划正式化？这些问题的答案将有助于更全面地了解新欧洲卫生联盟的行政层面，并阐明欧盟行政系统最近的一些演变。